Flavocure Biotech

The company is based at 701 East Pratt Street, Baltimore, MD 21202, USA.

Mission

Flavocure's mission is to deliver transformative, nature-inspired science to people with conditions that currently lack effective treatment options, making a meaningful difference in patients' lives.

Therapeutic focus areas

Flavocure concentrates on two major areas of medicine:

• Neurology / CNS disorders – developing a theranostic platform targeting neurological diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementias, frontotemporal dementias, cerebral amyloid angiopathy, post‑traumatic brain injury, chronic traumatic encephalopathy and related neurodegenerative conditions driven by neuroinflammation.
• Oncology – targeting aggressive and often rare cancers, including pancreatic cancer, brain cancers such as glioblastoma multiforme (GBM), brain metastases of major cancers (including lung and breast cancers), and hematologic malignancies such as myeloma and acute myeloid leukemia (AML).

Scientific approach

Flavocure's research is rooted in:

• Plant‑derived and nature‑derived molecules, including flavonoid derivatives, as the basis for new therapeutic candidates.
• Precision medicine and immunomodulation, particularly targeting disease‑associated and tumor‑associated microglia/macrophages.
• Nanomedicine and theranostics, combining targeted drug delivery with advanced imaging to diagnose and treat disease using a common platform.

Stage of development

Flavocure is a clinical‑stage biotechnology company. Its work spans:

• Preclinical discovery and development of novel therapeutic candidates.
• IND‑enabling studies in preparation for clinical trials.
• Early‑stage clinical development, including programs that have received FDA Orphan Drug Designation and Investigational New Drug (IND) clearance for pancreatic cancer.

The company does not offer direct clinical care or retail products; its primary activities are research, development and partnering to advance new therapeutics toward and through clinical trials.

• Email: info@flavocure.com
• Phone: 1‑877‑766‑0366
• Address: 701 East Pratt Street, Baltimore, MD 21202, USA

These channels are appropriate starting points for inquiries about research collaborations, media relations, investor interest and general questions.

Contact form categories

The online contact form allows visitors to identify themselves or their interest area by selecting from categories such as:

• Researcher
• Patient
• Physician
• Media
• Investor
• Other

Messages can then be submitted with a free‑text field for additional details.

Collaboration and partnering

Flavocure states on its website that it:

• Maintains strategic research collaborations with top academic institutions.
• Is interested in partnering opportunities with pharmaceutical and biotechnology companies.
• Focuses collaboration on discovering and developing new therapeutics for the treatment of cancer, CNS disorders, and potentially additional therapeutic areas in the future.

Parties interested in collaboration or partnering are invited to reach out via info@flavocure.com.

Newsletter

The website includes a newsletter sign‑up option under "Subscribe to Receive News from Flavocure Biotech."

• Visitors can enter an email address to subscribe.
• The newsletter is used to share company news, scientific updates, and media releases as they are published.

Specific newsletter frequency, content schedules, or subscriber policies are not detailed on the public site and therefore are not available in this agent's knowledge base.

• Dr. Henry L. C. Lowe, PhD – Executive Chairman and Co‑Founder

Co‑founder and Executive Chairman of Flavocure Biotech, Inc., and co‑inventor of the company's foundational intellectual property portfolio. A globally recognized authority in natural products drug discovery and development, with a career spanning academia, industry and public health. Holds a PhD in Medicinal Chemistry from the University of Manchester and has led work on plant‑derived therapeutics for cancer, neurodegenerative diseases and diabetes.

• Dr. Ngeh J. Toyang, PhD – Chief Executive Officer and Interim Chief Scientific Officer; Co‑Founder

Co‑founder and CEO of Flavocure Biotech, Inc. Trained in pharmacognosy, with more than 15 years of research experience at institutions including the University of Mississippi, Leiden University and the University of Maryland School of Medicine. Co‑inventor on patents covering Caflanone (FBL‑03G) and related platforms, and a key leader in advancing Flavocure's programs to clinical stage, including achieving two FDA Orphan Drug Designations and an IND clearance in pancreatic cancer.

• Dr. David Brooks, MD, PhD – Chief Medical Officer

Clinical and translational research leader with over 15 years of drug development experience, including oversight of programs that led to two FDA‑approved drugs. Has prepared clinical and biomarker sections for multiple IND applications and has specific experience in pancreatic adenocarcinoma trials, contributing to the approval of Abraxane for this indication. Holds MD and PhD degrees from Cornell University.

• Thomas Lang, PhD – Vice President, Quality and Regulatory Affairs

Pharmaceutical and biotech veteran with backgrounds in Chemistry and Pharmacy. Former President and Vice Chairman of Serono, Inc. Experience spans successful development and commercialization of products in HIV/AIDS, reproductive health, endocrinology, CNS, allergy immunotherapy and multiple sclerosis. At Flavocure he oversees IND‑enabling studies and preparation of IND packages for FDA submission.

• Douglas Liu – Chief Financial Officer

Finance executive with more than 20 years of experience in corporate finance and accounting roles at publicly traded biotech companies. Graduate of The Ohio State University (Finance and International Business), with extensive experience in SEC reporting and multiple rounds of public and private financing.

Board of directors

• Dr. Henry L. C. Lowe, PhD – Executive Chairman and Director

Co‑founder and Executive Chairman; see management bio above.

• Dr. Ngeh J. Toyang, PhD – Director

Co‑founder and CEO; see management bio above.

• Dr. Justin Grant, PhD, MBA – Director

Scientific and business leader with over 20 years of experience in medical and pharmaceutical product development, including senior roles at the University of Toronto, Princess Margaret Cancer Centre (STTARR Innovation Centre) and Avicanna Inc. Holds a PhD in Pharmaceutical Sciences and an MBA from the University of Toronto.

• David Afzali, MBA – Director

Founder and CEO of Innocatalyze Life Sciences, with more than three decades of leadership across pharmaceutical companies and global consulting firms. Has worked extensively with major biopharma companies on growth strategy and commercialization.

• Thomas R. Siegert, CPA – Director

Finance executive and strategic advisor, founder of Ridge CFO Partners and former Chief Financial Officer of IEEE. Background includes senior treasury and finance roles at Wyeth (now part of Pfizer). Holds an MBA in Finance and is a Certified Public Accountant.

Advisory team

• Dr. Louis Kirby, MD – Chief Medical Advisor, Neuroscience

Board‑certified neurologist and recognized expert in Alzheimer's disease and neurodegenerative disorders, with extensive experience in CNS drug development and clinical research.

• Dr. Eric Tanifum, PhD – Chief Scientific Advisor

Medicinal chemist and Associate Professor at Texas Children's Hospital/Baylor College of Medicine. Designer and co‑inventor of the NanoCaflanone™ platform and other nanoparticle‑based precision delivery systems targeting neurodegenerative disease and oncology pathways.

• Anthony Deasey – Chief Financial Advisor

Chartered accountant with over 35 years of CFO experience in public and private life science companies, with a track record of financing and successful exits.

• Dr. Saurabh Sewak, PhD – Business Advisor (via Sewaa Strategies, LLC)

Biotech veteran and CEO of Sewaa Strategies, with prior senior roles at Biogen, TESARO (now GSK), Ipsen and Foghorn Therapeutics. Experience across oncology, autoimmune inflammatory diseases, neurosciences and rare diseases.

• Dr. Thomas Woolf, PhD – Scientific Advisor

Pharmaceutical scientist and pharmacokinetics specialist with experience at companies such as Pfizer, Parke‑Davis/Warner‑Lambert and Elan Pharmaceuticals. Contributed to the discovery and development of multiple therapeutics, including a role in the development of Lipitor®.

This summary is intended to give a high‑level view of leadership and advisory expertise; the full biographies on the public website contain additional detail not reproduced here.

• Deliver drugs across the blood–brain barrier (BBB) to targets within the central nervous system (CNS) without mechanically, chemically or electrically disrupting the BBB.
• Diagnose and treat diseases that share a common biological driver: pathogenic microglial activation.
• Provide both high‑resolution MRI imaging and targeted drug delivery from a single, integrated system.

Biological targeting

NanoCaflanone™ focuses on:

• Disease‑associated microglia (DAMs) in neurodegenerative disease.
• Tumor‑associated microglia/macrophages (TAMMs) in the tumor microenvironment for brain cancers and metastases.

The platform centers on the CSF1‑R receptor expressed on inflamed or activated microglia, using it as a gateway for targeted imaging and therapeutic payload delivery.

Neurological disease applications

According to Flavocure's website, NanoCaflanone™ is being developed for multiple CNS indications associated with neuroinflammation, including:

• Alzheimer's disease (AD)
• Parkinson's disease (PD)
• Alzheimer's disease–related dementias (ADRD), such as:
• Lewy body dementias (LBD)
• Frontotemporal dementias (FTD)
• Cerebral amyloid angiopathy (CAA)
• Post‑traumatic brain injury (PTBI)
• Chronic traumatic encephalopathy (CTE)
• Other central nervous system pathologies in which disease‑associated microglia play a key role

Oncology applications

In oncology, NanoCaflanone™ aims to address:

• Malignant brain tumors such as glioblastoma multiforme (GBM)
• Brain metastases originating from major cancers, including lung and breast cancer

By targeting TAMMs and disease‑associated microglia within the tumor microenvironment, the platform seeks to enhance both diagnostic imaging and localized therapeutic delivery.

Diagnostic variant: NCDx™

• NCDx™ is described as a diagnostic variant of the NanoCaflanone™ platform.
• It functions as a first‑in‑class, non‑invasive molecular MRI probe targeting CSF1‑R to visualize neuroinflammation.
• Proof‑of‑concept data have been generated in preclinical models of Alzheimer's disease and Parkinson's disease, as reported in the company's materials.

How the platform works (high‑level)

Based on the public website description:

• Specialized nanoparticles/liposomes are engineered to cross the blood–brain barrier.
• These carriers can be formulated to:
• Provide MRI contrast for high‑resolution imaging of microglial activation.
• Carry therapeutic payloads (such as Caflanone‑based or other agents) to the same biological targets.
• The combination of imaging and therapy allows potential real‑time confirmation of whether a treatment has reached its intended cellular target.

Scope and limitations of information

• All details here are drawn from Flavocure's public website and associated summaries.
• Specific nanoparticle compositions, dosing regimens, clinical protocols, and human safety/efficacy outcomes are not provided on the public site and therefore are not available in this agent's knowledge base.
• Any information about patient‑specific treatment, clinical trial eligibility, or medical decision‑making must come directly from Flavocure Biotech or treating healthcare professionals.

According to 2022 U.S. SEER data cited by Flavocure:

• New cases: 60,430
• Deaths: 48,220
• Share of all cancers: ~3% of incident cancers and ~7% of all cancer deaths
• 5‑year relative survival: 10.8%
• Median age at diagnosis: 70 years
• Median age at death: 72 years

Pancreatic cancer, including rare forms such as pancreatoblastoma, is highlighted as an area with a dire need for transformative therapies. Flavocure's Caflanone‑based programs target this disease area.

Brain and other nervous system cancers (including glioblastoma)

For cancers of the brain and other nervous system (which include glioblastoma and other brain tumors), 2022 SEER data summarized on the site indicate:

• New cases: 20,050
• Deaths: 18,280
• Share of all cancers: ~1.3% of incident cancers and ~3% of all cancer deaths
• 5‑year relative survival: 32.5%
• Median age at diagnosis: 59 years
• Median age at death: 66 years

Glioblastoma and related brain cancers are described as having particularly poor prognoses, motivating development of new approaches that can reach intracranial targets.

Myeloma

For myeloma, a blood cancer originating from plasma cells, the 2022 SEER statistics cited on the site are:

• New cases: 34,470
• Deaths: 12,640
• Share of all cancers: ~1.8% of incident cancers and ~2.1% of all cancer deaths
• 5‑year relative survival: 57.9%
• Median age at diagnosis: 69 years
• Median age at death: 75 years

Flavocure notes myeloma among the indications linked to CSF1‑R–mediated biology.

Acute myeloid leukemia (AML)

For acute myeloid leukemia (AML), 2022 SEER statistics highlighted on the website include:

• New cases: 20,050
• Deaths: 11,540
• Share of all cancers: ~1% of incident cancers and ~1.8% of all cancer deaths
• 5‑year relative survival: 30.5%
• Median age at diagnosis: 68 years
• Median age at death: 73 years

How these data relate to Flavocure's work

• These figures describe the disease burden in the general population; they are not outcomes from Flavocure's therapies or clinical trials.
• Flavocure uses such epidemiologic data to underscore the medical need for new treatments in pancreatic cancer, brain tumors (including glioblastoma), myeloma, AML and other serious cancers.
• Detailed information on specific Flavocure clinical studies, trial results, or patient‑level outcomes is not provided on the public website and is therefore not available in this agent's knowledge base.

| Product / Platform | Primary targets | Primary disease areas | Developmental stage (per website) | Notes | | --- | --- | --- | --- | --- | | Caflanone (FBL‑03G) | CSF1‑R and KRAS pathways | Pancreatic cancer / pancreatoblastoma | IND‑ready; FDA Orphan Drug Designation for pancreatic cancer | Lead oncology and CNS candidate derived from flavonoid chemistry. Program includes a cleared IND for a Phase I trial in pancreatic cancer, as described in company materials. | | Caflanone – GBM / Myeloma program | CSF1‑R | Glioblastoma multiforme (GBM), myeloma | Pre‑clinical | Explores Caflanone‑based strategies in solid and hematologic tumors associated with tumor‑associated microglia/macrophages. | | Caflanone / HLNT‑06 | CK2 and CSF1‑R | CNS indications | Pre‑clinical / platform integration | Combines Caflanone with additional targeting of CK2 for CNS applications. | | NanoCaflanone™ Platform | CSF1‑R on disease‑associated microglia and tumor‑associated microglia/macrophages | Neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, related dementias, traumatic brain injury–related conditions) and oncology (e.g., malignant brain tumors, brain metastases) | Preclinical platform with proof‑of‑concept imaging and delivery data | Nanoparticle‑based theranostic platform designed to cross the blood‑brain barrier and enable targeted imaging plus drug delivery. | | NCDx™ | CSF1‑R | Neurological disorders, including Alzheimer's disease and Parkinson's disease | Proof‑of‑concept shown in preclinical models | Diagnostic variant of the NanoCaflanone™ platform functioning as a non‑invasive molecular MRI probe of neuroinflammation. | | NCThera™, NCRTx™, NCPRx™ | Multiple targets | Oncology and CNS indications | Early‑stage / platform‑level R&D | Families of nanoparticle‑enabled therapeutics and combination regimens being explored for oncology and CNS applications.

Key platform characteristics (as described on the website)

• Targeted microglia modulation – Several pipeline programs act on CSF1‑R, a receptor implicated in microglial activation, proliferation and survival, and in tumor‑associated microglia/macrophages.
• Blood–brain barrier (BBB) access – NanoCaflanone™ is designed to deliver cargo across the BBB without mechanical, chemical or electrical disruption of the barrier.
• Theranostic design – The platform is structured to support both:
• Diagnostic imaging (e.g., MRI‑visible liposomal/nanoparticle constructs such as NCDx™), and
• Therapeutic delivery (drug payloads carried by the same or related nanoparticles).
• Multi‑indication potential – By focusing on shared biology (pathogenic microglial activation and tumor microenvironments), technologies are positioned to be applied across numerous CNS and oncology indications.

Regulatory designations (as quoted on the site)

• Caflanone‑based programs have received FDA Orphan Drug Designations in pancreatic cancer.
• An FDA‑cleared Investigational New Drug (IND) application supports initiation of a Phase I clinical trial in pancreatic cancer, as described in the company's materials.

Specific trial designs, enrollment status, sites and timelines are not detailed on the public website and are therefore not available in this agent's knowledge base.

Ask anyway — the agent will say plainly that it is not published rather than guess.